Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -0.98% 50.50 380,834 15:46:15
Bid Price Offer Price High Price Low Price Open Price
50.00 51.00 53.50 49.25 53.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.58 -7.73 -3.82 87
Last Trade Time Trade Type Trade Size Trade Price Currency
16:20:21 O 4,760 50.00 GBX

Angle (AGL) Latest News (3)

More Angle News
Angle Investors    Angle Takeover Rumours

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
20/10/202015:13ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY3,411
05/8/202013:50ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET11,390
28/8/201812:29ANGLE plc (AGL) One to Watch -
02/7/201812:06Still time to look at Angle (AGL)-
14/5/201809:44ANGLE (AGL) Strategic Move-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-10-20 15:20:2150.004,7602,380.00O
2020-10-20 14:50:3150.011,037518.60O
2020-10-20 14:45:2551.004,7352,414.85O
2020-10-20 14:43:0250.44966487.25O
2020-10-20 14:35:2950.441,970993.67O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 51p.
Angle Plc has a 4 week average price of 49.25p and a 12 week average price of 49.25p.
The 1 year high share price is 80p while the 1 year low share price is currently 43.50p.
There are currently 172,754,816 shares in issue and the average daily traded volume is 262,754 shares. The market capitalisation of Angle Plc is £87,241,182.08.
sicilian_kan: Surely the right question to ask is what % of de novo applications are successful? There are no statistics on this that I have found. The only fair comparison for the moment is to look at other companies who have successfully passed their clinical trials and to look at their success rates in getting approved by the FDA on the back of that clinical data. That is the position AGL are in - not the position of a company doing P3, i.e. still doing the clinical trials. So there is nothing directly on point in the public domain, but: - if you look at drugs, 87.5% of NDA and BLA applications are successful - if you look at medical devices, 85% of 510k applications are successful I think it fair to say that the chance of getting approved having already had a Q-submission is likely to be far higher than that. But even if you take the above statistics, there is an 85+% chance of Parsortix being approved. The current share price, on those statistics, is massively undervalued.
miavoce: Hi bones you say 'If you are unaware that the majority of companies fail at this level then your in the wrong game . I suggest you look at the history of l small cap companies for this evidence'. I recall that several years ago somebody said something very similar to this (it may even have been yourself) and so I researched the failure rate of small AIM companies and demonstrated that, contrary to your assertion, most do not fail. Perhaps you meant that most companies that apply for FDA approval for a medical device via the de novo route after a successful Q-Submission go on to fail ? Unfortunately I cannot find any statistics on this - have you found any ? Regarding the lack of share price movement, there may be some investor fatigue given the time it has taken to get to this point but I suspect that the selling by Jupiter is what is holding the share price back rather than the market not believing that FDA approval will be granted. Just my opinion of course and no more or less valid than yours.
bones698: Mia certainly The first point is easily justified by the lack of sharerpiece movement. I don't control the share price the market does and so the complete lack of movement shows that many investors and the market don't believe . If you are unaware that the majority of companies fail at this level then your in the wrong game . I suggest you look at the history of l small cap companies for this evidence Waterloo I agree with your points that there is a better chance with the research provided but still think we are a long way apart on what the chance is as I have stated before. Many think it's a 50 50 chance now . Myself I believe it's in the region of 5% chance of success . AN chose this route ,one which has proven far more difficult than the alternatives but is doing what he can to get it there but even so I believe it will get knocked back . If it does the question then is does he partner up now after so much dilution or stick to this path which could go on for many years again . As always good points but can be looked at from both perspectives with very different outcomes . At least the wait wont be long this time before we have a decision , that ts a bonus especially for long term holders ,even I believe you have suffered long and hard lol I can't comment on the takeover as I haven't followed the story tbh. It no doubt will have some relevance of agl get approval but not sure how much without it The good thing with parsortix is being diagnostic it limits the things it can get knocked back for . I have seen the fda come up with some very good excuses not to give drugs the go ahead but with this those are reduced somewhat . I believe more evidence and trials will be their go to get out clause though. I know a lot has been done with the false positives but think that's an area which could give reason to demand more data even with the mountains of it provided by agl.
bones698: Don't bother looking at the share trades to try and figure out who's buying and selling etc ,the simple answer is you will never know what's going on behind the scenes . The simple fact is the share price is where it is and no conspiracy theories are going to change that . Why this isn't higher after submission comes down a lot to the number of years agl has been trying to get it and still hasn't and so nobody believes this time will be any different . A fair assumption imo . I feel failure to get approval will result an initial drop in the share price to mid 30's on the bad news . From there it's anyone's guess but the fact more funds would need to be raised to last another 3 years or so while they gather more data and resubmit could really cause some damage to the shareprice . I was pondering buying some if the downside was limited but on second thoughts can still see a big loss of my long term beliefs prove correct . 100m mkt cap will look high without fda approval and not much cash in the bank . If you fancy a gamble 50p doesn't look a bad price given the submission but like with a lot of companies at this level the failures far outnumber the successes by 20 to 1 . Kind of gives an indication of the challenge to pick the winner . This is still a gamble and no amount of research and analysis will change that . Everything depends on the fda decision and has done for many years . Will it come this time or not it's that simple .
banshee: The difference between 85p last October and now relates to the liklehood of further fundraising before approval as well as Jupiter selling, Had AGL submitted in March, deadline they missed because of Covid, of it is likely there would have been a good chance of approval without the need for funds prior to that event. Whilst AGL could get approval in 6 months, when they they say that is the earliest time, it means in practice it is likely to take longer given the complexity of the application and their general history of (often very substantial) over optimism. Also someone like Exact or Grail could easily ending up buying AGL it is disingenuous to suggest that rival much larger companies are pursuing ctDNA because they think CTCs cannot be trapped. There are other issues involved. Still, despite all that I'd be suprised if AGL did not achieve at least 5 bagger status from here over the next 2-3 years.
chippyfriday: Thanks to AGL for not taking fda submission to the wire, I confess to a few anxious moments in the last few weeks! I note that A.N thanked the 400 MBC patients (and the 1000 healthy volunteers) for taking part in the research, so while we all want to see an increase in the share price, success here will mean a great deal more to cancer sufferers in terms of improved treatment and hopefully one day, earlier diagnosis! SK - Thanks, look forward to seeing the new header.
miavoce: Given the huge jump in the AGL share price when the original RNS came out (the one announcing the research that revealed that Digoxin can break down clusters), imagine what kind of jump we could see if the Phase 1 gives similarly positive results in humans....(I presume AGL would announce this). Edit : Next June isn't far away....
banshee: Dear Gawd, this is an existing approved drug with a known safety profile, not a novel compound, time to market would be much faster, with P2 starting as early as next year. A successful P2 would create a dilemna for regulators as well if it halted metastices (as it did in human cancers in mice if I recall), in addition to creating Worldwide Headlines and propelling the share price into the stratosphere. AGL are not funding the trial just providing kit AFAIK.
banshee: I don't follow RENX but certainly they have a substantial number of ADR/ADS issued recently, the issue is that ADR/S almost never drive the share price but tend to just track the primary exchange, so you will be relying on the AIM to do the driving if it is a dual listing, and the AIM is highly unlikely to move AGL to US valuations proper.., that is not to say there isn't significant scope to move up. hTtps:// "today announces the closing of its global offering of an aggregate of 11,000,000 new ordinary shares, including 5,485,000 American Depositary Shares (“ADSs”) at a price of US$13.50 per ADS and 30,000 ordinary shares at a price of £5.37 per ordinary share (at an exchange rate of GBP:USD 1:1.2563), for aggregate gross proceeds of approximately US$74.3 million" "Each ADS offered represents two ordinary shares of the Company. The ADSs were offered in a registered public offering in the United States and the Company’s ordinary shares were offered in a concurrent private placement in Europe and other countries outside of the United States"
spaceparallax: One day, the AGL share price will reflect the astonishing efficacy of this simply amazing Parsortix technology.
Angle share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201021 03:31:45